P
IONS icon

&Partners’s Ionis Pharmaceuticals IONS Stock Holding History

&Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$819K Buy
10,909
+1,186
+12% +$93.6K ﹤0.01% 1411
2025
Q4 		$769K Sell
9,723
-2,940
-23% -$221K ﹤0.01% 1372
2025
Q3 		$828K Buy
12,663
+905
+8% +$44.2K 0.01% 1177
2025
Q2 		$465K Buy
11,758
+754
+7% +$24.7K ﹤0.01% 1396
2025
Q1 		$343K Buy
11,004
+687
+7% +$22.5K ﹤0.01% 1338
2024
Q4 		$359K Buy
10,317
+711
+7% +$26.6K ﹤0.01% 1239
2024
Q3 		$385K Buy
+9,606
New +$447K 0.01% 987

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

&Partners's IONS Position: Q1 2026 in Review

&Partners increased its Ionis Pharmaceuticals (IONS) stake by 12% in Q1 2026, buying an estimated $93.6K and bringing the position to 10,909 shares worth $819K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

&Partners first reported a position in IONS in Q3 2024 and has held it in 7 quarters since. The position peaked at $828K in Q3 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • &Partners held 10,909 shares of Ionis Pharmaceuticals worth $819K as of Q1 2026.
  • &Partners bought 1,186 Ionis Pharmaceuticals shares in Q1 2026, an estimated $93.6K.
  • Ionis Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1411 holding.
  • &Partners first reported a position in Ionis Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • &Partners's Ionis Pharmaceuticals position peaked at $828K in Q3 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.